» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing


More Information on Drug Labeling

Food and Drug Administration Petition on Generic Drug Labeling

August 29, 2011, updated April 27, 2015

View the petition (PDF).

View FDA’s response to the petition (PDF).

View the proposed rule (PDF).

View testimony of Allison Zieve, Director of Public Citizen Litigation Group before the Committee on Energy and Commerce, Subcommittee on Health, U.S. House of Representative, March 3, 2014. (Postponed to April 1)

View Public Citizen’s comments on the FDA’s proposed rule to allow generic drug manufacturers to update product labeling with newly discovered risk information, March 13, 2014.

View Public Citizen’s additional comments on the FDA’s proposed generic drug labeling rule and an industry alternative, April 27, 2015.

View Public Citizen press statement about FDA delaying its proposed rule

View press release.

In August 2011, Public Citizen petitioned the Food and Drug Administration (FDA) to revise its regulations to allow generic drug manufacturers to update product labeling to warn patients about newly discovered risks associated with their drugs. Such revisions would cure the illogical disparity between labeling regulations for generic companies and brand-name companies, as brands are permitted to promptly revise drug labeling to provide updated safety information.

The inability of generic companies to revise labeling poses a safety problem because safety issues often arise years after the generic version of a drug has entered the market – sometimes more than a decade later. For example, as Public Citizen explained in a report issued in June 2013, at least 53 drugs approved by the FDA more than 10 years ago have required new black-box warnings over the past five years.

In November 2013, the FDA granted our petition and issued a proposed rule that, when finalized, would establish procedures for generic drug manufacturers to change product labeling to reflect new information in advance of FDA's review of the change. As the FDA explained, the proposed rule will improve the communication of important drug safety information about generic drugs to both prescribers and patients.

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.